Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells
N Magan, RJ Isaacs, KM Stowell - Anti-cancer drugs, 2012 - journals.lww.com
Adjuvant therapies can incorporate a number of different drugs to minimize the cardiotoxicity
of cancer chemotherapy, decrease the development of drug resistance and increase the
overall efficacy of the treatment regime. Topoisomerase IIα is a major target of many
commonly used anticancer drugs, where cell death is brought about by an accumulation of
double-strand DNA breaks. Poly (ADP-ribose) polymerase (PARP)-1 has been extensively
studied for its role in the repair of double-strand DNA breaks, but its ability to add highly …
of cancer chemotherapy, decrease the development of drug resistance and increase the
overall efficacy of the treatment regime. Topoisomerase IIα is a major target of many
commonly used anticancer drugs, where cell death is brought about by an accumulation of
double-strand DNA breaks. Poly (ADP-ribose) polymerase (PARP)-1 has been extensively
studied for its role in the repair of double-strand DNA breaks, but its ability to add highly …
